ZA895909B - Cytotoxic drug conjugates - Google Patents

Cytotoxic drug conjugates

Info

Publication number
ZA895909B
ZA895909B ZA895909A ZA895909A ZA895909B ZA 895909 B ZA895909 B ZA 895909B ZA 895909 A ZA895909 A ZA 895909A ZA 895909 A ZA895909 A ZA 895909A ZA 895909 B ZA895909 B ZA 895909B
Authority
ZA
South Africa
Prior art keywords
drug conjugates
cytotoxic drug
cytotoxic
conjugates
drug
Prior art date
Application number
ZA895909A
Other languages
English (en)
Inventor
David Arthur Johnson
Arthur Johnson David
Bennett Coleman Laguzza
Coleman Laguzza Bennett
William Leonard Scott
Leonard Scott William
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA895909B publication Critical patent/ZA895909B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA895909A 1988-08-08 1989-08-02 Cytotoxic drug conjugates ZA895909B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/229,941 US5028697A (en) 1988-08-08 1988-08-08 Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers

Publications (1)

Publication Number Publication Date
ZA895909B true ZA895909B (en) 1991-04-24

Family

ID=22863313

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA895909A ZA895909B (en) 1988-08-08 1989-08-02 Cytotoxic drug conjugates

Country Status (14)

Country Link
US (1) US5028697A (de)
EP (1) EP0354729B1 (de)
JP (1) JPH02256700A (de)
KR (1) KR900002803A (de)
CN (1) CN1040204A (de)
AU (1) AU619328B2 (de)
DE (1) DE68912232T2 (de)
DK (1) DK382889A (de)
HU (1) HU208161B (de)
IL (1) IL91181A0 (de)
MX (1) MX165003B (de)
NZ (1) NZ230199A (de)
PT (1) PT91371B (de)
ZA (1) ZA895909B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
ZA914625B (en) * 1990-06-22 1993-02-24 Lilly Co Eli In vivo targeting with bifunctional antibodies
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
US5556623A (en) * 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
JPH072895A (ja) * 1993-04-28 1995-01-06 Eli Lilly & Co 抗体−薬物複合体
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
US6906182B2 (en) 2000-12-01 2005-06-14 Cell Works Therapeutics, Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (de) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Spezifische bindungsproteine und ihre verwendung
BRPI0406647A (pt) * 2003-01-06 2005-12-06 Angiochem Inc Método para transportar um composto através da barreira sanguìnea do cérebro
US20080312201A1 (en) * 2004-09-10 2008-12-18 Patrick Fogarty Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
US7557182B2 (en) * 2005-02-18 2009-07-07 Angiochem Inc. Molecules for transporting a compound across the blood-brain barrier
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
JP5436856B2 (ja) 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
AU2006318216C1 (en) 2005-11-28 2012-02-16 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2542152T3 (es) 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
US7998967B2 (en) 2008-03-03 2011-08-16 Tosk, Incorporated Methotrexate adjuvants to reduce toxicity and methods for using the same
TR201905480T4 (tr) * 2008-04-18 2019-05-21 Angiochem Inc Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
MX2011004019A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de etoposido y doxorubicina para entrega de farmacos.
CA2745524C (en) * 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
WO2010121379A1 (en) 2009-04-20 2010-10-28 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
AU2010268726A1 (en) 2009-07-02 2012-01-19 Angiochem Inc. Multimeric peptide conjugates and uses thereof
CN110124039A (zh) 2011-05-16 2019-08-16 建新公司 使用甲氨蝶呤诱导免疫耐受性
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
RU2729194C2 (ru) 2013-12-27 2020-08-05 Займворкс Инк. Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
AU2015318556C1 (en) 2014-09-17 2021-01-07 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
WO1983000150A1 (en) * 1981-07-02 1983-01-20 Walton, Alan, G. Glycosaminoglycan drug complexes
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0121388B1 (de) * 1983-03-30 1990-06-13 Lilly Industries Limited Immunoglobulinkonjugate
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
DE3788058T2 (de) * 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
IE63869B1 (en) * 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
US4918165A (en) * 1987-07-16 1990-04-17 Ophthalmic Research Corporation Mitotic inhibitor and method for preventing posterior lens capsule opacification after extracapsular extraction

Also Published As

Publication number Publication date
MX165003B (es) 1992-10-13
PT91371A (pt) 1990-03-08
PT91371B (pt) 1995-05-04
HU208161B (en) 1993-08-30
EP0354729B1 (de) 1994-01-12
IL91181A0 (en) 1990-03-19
HUT50850A (en) 1990-03-28
EP0354729A2 (de) 1990-02-14
DK382889D0 (da) 1989-08-04
CN1040204A (zh) 1990-03-07
JPH02256700A (ja) 1990-10-17
US5028697A (en) 1991-07-02
NZ230199A (en) 1991-09-25
KR900002803A (ko) 1990-03-23
AU619328B2 (en) 1992-01-23
EP0354729A3 (de) 1991-04-17
AU3933889A (en) 1990-02-08
DE68912232T2 (de) 1994-05-19
DK382889A (da) 1990-02-09
DE68912232D1 (de) 1994-02-24

Similar Documents

Publication Publication Date Title
IL91181A0 (en) Cytotoxic drug conjugates
ZA895908B (en) Cytotoxic drug conjugates
GB8822857D0 (en) Pharmaceutical formulations
EP0335545A3 (en) Pharmaceutical formulations for parenteral use
GB9410236D0 (en) Cytotoxic drug therapy
ZA892315B (en) Pharmaceutical formulations for parenteral use
HUT53126A (en) Antibody medicament conjugates
GB2228922B (en) Packaging drugs
EP0443027A4 (en) Drug composition
ZA899948B (en) Pharmaceutical preparation
IE892534L (en) Cytotoxic drug conjugates
IE892533L (en) Cytotoxic drug conjugates
GB8807505D0 (en) Pharmaceutical combinations
ZA893463B (en) Drug adsorbates
GB8901158D0 (en) Administering drugs
IE883489L (en) Drug-monoclonalantibody conjugates
IL92583A0 (en) Tolerogenic immunoglobulin-protein conjugates
GB8820343D0 (en) Pharmaceutical formulations
GB8820273D0 (en) Pharmaceutical formulations
GB8825297D0 (en) Pharmaceutical formulations
GB8828994D0 (en) Pharmaceutical formulations
GB8816609D0 (en) Pharmaceutical formulations
GB8813402D0 (en) Pharmaceutical formulations
GB8820272D0 (en) Pharmaceutical formulations
GB8820271D0 (en) Pharmaceutical formulations